JDRF is striving to accomplish a feat that has never been achieved before: permanently turning off an autoimmune response in humans. The JDRF Immunotherapy Program aims to turn off the deadly attack against beta cells that causes type 1 diabetes (T1D). We power groundbreaking research and development of new therapies that will stop the autoimmune attack at its earliest stages.
Our immune systems protect us against threats from within and without. In people with T1D, the immune system mistakes the body’s own cells for dangerous invaders and targets the pancreas’ insulin-producing beta cells. As a result of beta cell death, people with T1D depend on external insulin to survive.
Disable overactive immune assassins
so progression to T1D never happens
Boost “good” cells
that can control and inhibit killer cells
Restore the environment
for continued immune control against beta cells
“Living with the burden of T1D is far from easy. It can bring you to your knees. But after being involved in an immunotherapy research trial and seeing the results first hand, I know a cure is possible. JDRF is going to make it happen.”
18 years old, diagnosed at age 16
Many Paths, One Purpose
Our research into immunotherapy technologies is just one potential pathway to finding a cure. Explore JDRF’s ambitious research portfolio.
To date, more than $145 million has been invested by JDRF on immunotherapy research. We are striving to accomplish a feat that has never been achieved before: permanently turning off an autoimmune response in humans.